Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.24.2.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2024
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 151,791 $ 180,571
Short-term available-for-sale investments 1,072 23,739
Accounts receivable, less allowance for doubtful accounts of $4,386 and $4,738, respectively 241,394 218,468
Inventories 179,731 171,638
Current assets held-for-sale 9,773  
Other current assets 33,658 27,066
Total current assets 617,419 621,482
Property and equipment, net 251,154 226,200
Right-of-use assets 91,285 98,326
Goodwill 972,663 872,737
Intangible assets, net 507,081 534,645
Other assets 264,265 285,302
Total assets 2,703,867 2,638,692
Current liabilities:    
Trade accounts payable 37,968 25,679
Salaries, wages and related accruals 49,818 36,747
Accrued expenses 24,886 14,880
Contract liabilities 27,930 23,069
Income taxes payable 3,706 12,022
Operating lease liabilities - current 12,920 11,199
Contingent consideration payable   3,500
Other current liabilities 2,151 1,413
Total current liabilities 159,379 128,509
Deferred income taxes 55,863 88,982
Long-term debt obligations 319,000 350,000
Operating lease liabilities 87,618 93,766
Other long-term liabilities 13,157 10,919
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 158,216,258 and 157,641,914 respectively 1,582 1,576
Additional paid-in capital 820,337 721,543
Retained earnings 1,325,247 1,309,461
Accumulated other comprehensive loss (78,316) (66,064)
Total Bio-Techne's shareholders' equity 2,068,850 1,966,516
Total liabilities and shareholders' equity $ 2,703,867 $ 2,638,692